Follow us for updates
© 2022
Read the Story →

AstraZeneca COVID Vaccine is Cheap, Can Keep in Normal Refrigerator

Five facts about the much-anticipated jab.
by Agence France Presse
Jan 2, 2021
Photo/s: Joel Saget/AFP

LONDON -- Cheap and easy to store, the AstraZeneca Oxford vaccine approved by the British regulator has given a shot in the arm to the global fight against coronavirus. 

Here are five facts about the much-anticipated vaccine. 


The AstraZeneca/Oxford vaccine has the major advantages of being inexpensive, costing about £2.50 (P164) per dose, and easy to store. 

It can be kept at normal refrigerator temperatures of between two and eight degrees Celsius, making it ideal for large-scale vaccination programs. 

By contrast, the Moderna vaccine needs to be stored at -20C, while the Pfizer/BioNTech product must be kept at -70C.


Got COVID Vaccine Questions? Here are Expert Answers 

How Much Will COVID-19 Vaccines Cost? 

Mutant strain

The vaccine should be capable of fighting the new variant of the coronavirus responsible for a surge of cases in the United Kingdom, according to AstraZeneca chief executive Pascal Soriot.

"So far, we think the vaccine should remain effective. But we can't be sure, so we're going to test that," he told the Sunday Times.

Continue reading below ↓

New versions are being developed just in case, he revealed, adding: "You have to get prepared."

British product

The vaccine developed by British firm AstraZeneca, working alongside Oxford University, is the second to be approved by the independent Medicines and Healthcare products Regulatory Agency (MHRA).

The Pfizer/BioNTech vaccine has been deployed in Britain since Dec. 8, with almost 800,000 receiving their first dose, according to British Prime Minister Boris Johnson. 

His government is battling one of the world's worst outbreaks, with more than 71,000 deaths so far of those testing positive for the disease.

Britain has ordered 100 million doses of the AstraZeneca/Oxford vaccine, 40 million of which will be available by the end of March, with vaccinations scheduled to begin on January 4. 

AstraZeneca said it expects to be able to manufacture about three billion doses of its vaccine worldwide in 2021. 


What is the Philippines COVID Vaccine Plan?

Continue reading below ↓
Recommended Videos

Who Gets COVID-19 Vaccine in Philippines First?

What If You Don't Want a COVID Vaccine?


The vaccine is "virus-vectored", meaning it is a version of a virus that normally infects chimpanzees and has been modified with a portion of the COVID-19 coronavirus called the "spike protein" to fire the immune system. 

Once in human cells, the vaccine should help stimulate the production of antibodies that recognizee the virus. 

The vaccine is "safe and effective", according to data published by The Lancet medical journal on Dec. 8, with only one of the of the 23,754 volunteers who participated in the trials experiencing "possibly-related severe side effects". 

This was a case of rare neurological condition transverse myelitis that forced the temporary suspension of trials. 

Result Confusion

The British laboratory announced in interim findings in November that its vaccine was on average 70% effective, compared with more than 90% for Pfizer/BioNTech and Moderna

Continue reading below ↓

The efficacy of the AstraZeneca/Oxford vaccine was 90% for volunteers who first received only a half-dose and then a full dose one month later, but only 62% for another group that was vaccinated with two full doses one month apart. 

The injection of a half-dose was conducted by accident, raising criticism over the robustness of the results and prompting the company to announce on Nov. 26 that an "additional study" would be held into the efficacy of the reduced dosage. 

"We think we have figured out the winning formula and how to get efficacy that, after two doses, is up there with everybody else," Soriot told the Sunday Times.

Latest Headlines
Read Next
Recent News
With the reopening of several local destinations, this app has never been more timely.
The focus should be on the poor, incoming senator said.
GCash isn't just about paying bills and transferring funds.
You'll need a bigger wallet, incoming BSP gov says.
The news. So what? Subscribe to the newsletter that explains what the news means for you.
The email address you entered is invalid.
Thank you for signing up to On Three, reportr's weekly newsletter delivered to your mailbox three times a week. Only the latest, most useful and most insightful reads.
By signing up to newsletter, you agree to our Terms of Service and Privacy Policy.